News | Intra-Aortic Balloon Pumps (IABP) | November 05, 2018

Maquet/Datascope Intra-Aortic Balloon Pumps Might Fail on Battery Power

Vendor issues letter to healthcare providers warning of 75 cases of device shut down

he U.S. Food and Drug Administration (FDA) is evaluating recent reports of Getinge's Maquet/Datascope intra-aortic balloon pump (IABP) devices shutting down while running on battery power.

November 5, 2018 — The U.S. Food and Drug Administration (FDA) is evaluating recent reports of Getinge's Maquet/Datascope intra-aortic balloon pump (IABP) devices shutting down while running on battery power. The company issued a letter to providers warning them about this issue Nov. 1, 2018. 

IABPs are used on critically-ill patients in health care facilities, including during transport. The vendor said an interruption in treatment can result in serious patient injury or death.

The Maquet/Datascope IABP is a cardiac assist device placed in the descending aorta, just distal to the left subclavian artery. The device is an electromechanical system used to inflate and deflate intra-aortic balloons, which provides temporary support to the heart's left ventricle by increasing coronary perfusion and reducing left ventricular work. Getinge manufactures the following Maquet/Datascope IABP devices: Cardiosave (Hybrid and Rescue), CS300 and CS100/CS100i.

Since 2017, the FDA has received more than 75 medical device reports of Maquet/Datascope IABP devices shutting down while running on battery, leading to pump stop and loss of hemodynamic support. Five of these reports described three patient deaths, although the deaths cannot be definitively attributed to the device shutting down. Other reports describe serious patient injury such as a sudden drop in blood pressure or the need for resuscitation. At least six reports indicated that there was no alarm warning before the device shutdown.

The company said the onset of the shutdown as described in the reports ranges from immediately following disconnection of the IABP from AC power (electricity) to within the expected battery run time.

In addition to device shutdown, there are reports describing several battery issues that could lead to patient harm, such as the device not charging the battery, the battery charge indicator not working properly or not showing the correct status of the battery charge, or the battery depleting sooner than expected.

"At this time, the root cause or incidence rate of these IABP devices shutting down while on batteries is not known. Although we are concerned about the device shutdown events associated with Maquet/Datascope IABPs, we recognize that these systems may be the best option for circulatory support for some patients. The FDA wants to ensure you are aware of these device failures that have been observed in patients treated with Maquet/Datascope IABPs and reported to the FDA," the company stated it is letter.

 

Recommendations for Providers

The FDA recommends that healthcare providers should follow each device's operating instructions manual for recommendations on usage, charging, maintenance and storage of the system batteries, since battery run times and discharge cycles vary between IABP models. 

In addition, the FDA recommends that users and servicers of Maquet/Datascope IABP devices should:
   • Ensure the IABP system is plugged into an AC outlet whenever possible during patient use to prevent the battery from depleting.
   • Ensure the IABP system is plugged into an AC outlet when the system is not in use. The batteries should be kept at a full charge even when the IABP is not in use.

When transporting patients within or between facilities, please refer to the system's Operating Instructions Manual for recommendations for portable/battery operation. For example:
   • Prior to portable operation, the battery should be fully charged.
   • Additional charged batteries should be on hand during transport, if applicable for the system. 
   • Ensure the batteries are properly seated in the battery compartment/charger. 
   • Periodically check battery run time and replace batteries as required, as recommended in each system's Operating Instructions Manual. A reduction in run time can occur over a battery's life for reasons such as age, storage temperature and discharge depth. 

Batteries should be replaced:
   • After reaching the maximum number of charge-discharge cycles. 
   • When the battery provides less than the minimum expected run time.
   • When the labeled lifetime of the battery is reached.
   • If the battery is broken, cracked, leaking or damaged. 

The vendor encourages providers to report to the FDA events of IABP devices shutting down while running on batteries, as well as any other battery issues that occur. Voluntary reports can be submitted through MedWatch, the FDA Safety Information and Adverse Event Reporting program. Healthcare personnel employed by facilities subject to FDA's user facility reporting requirements should follow the reporting procedures established by their facilities. Prompt reporting of adverse events can help the FDA identify and better understand the risks associated with medical devices.

When possible, return devices associated with, or suspected to be associated with, any adverse events or device malfunction to the manufacturer for evaluation to help them and the FDA better understand the issue.

The FDA is working with the device manufacturer to better understand these device shutdown events while running on battery for Maquet/Datascope IABPs, and any contributing factors. The FDA will keep the public informed if significant new information becomes available.

Links to Related Maquet IABP FDA Recalls:

Getinge Issues Worldwide Voluntary Correction of Maquet/Getinge Cardiosave Intra-Aortic Balloon Pump

Maquet Datascope Corp./Getinge Group Recalls the Cardiosave Hybrid and Cardiosave Rescue Intra-Aortic Balloon Pumps (IABPs) Due to Possible Malfunction and Failure at High AltitudesGetinge Issues Worldwide Voluntary

Correction of Maquet/Getinge Cardiosave Intra-Aortic Balloon Pump (IABP) For Interruption and/or Inability to Start Therapy at Altitudes above 3,200 Feet/975 Meters (September 20, 2018)

Related Content

Gallery | Cath Lab | October 31, 2019
This is a photo essay of the interventional cardiology and structural heart technologies on the expo floor and discus
The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

Technology | Cath Lab | October 28, 2019
Office based labs (OBLs) and ambulatory surgery centers (ASCs) require a fresh perspective from imaging vendors.
Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

News | Cath Lab | October 28, 2019
October 28, 2019 — Leaders within University Hospitals and the Harrington Heart and Vascular Institute had a vision t
OmniVision Announces Guinness World Record for Smallest Image Sensor

OmniVision's OVM6948 CameraCubeChip, a fully packaged, wafer-level camera module measuring 0.65mm x 0.65mm x 1.158mm, built on OmniVision's OV6948, winner of the Guinness World Record for “The Smallest Image Sensor Commercially Available.”

News | Cath Lab | October 22, 2019
October 22, 2019 — OmniVision Technologies Inc.
People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes. 

Feature | Cath Lab | October 03, 2019
October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with pe
Two Stents Implanted in Democratic Presidential Candidate Bernie Sanders, suffers chest pain
News | Cath Lab | October 02, 2019 | Dave Fornell, Editor
October 2, 2019 — Democratic presidential candidate Sen.
Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival
News | Cath Lab | September 25, 2019
Ten-year survival rates are similar for bypass surgery and coronary stenting with drug-eluting stents in randomized...
Complete Revascularization Superior to Culprit Lesion-only Intervention
News | Cath Lab | September 10, 2019
An international randomized trial has shown that complete revascularization reduces major cardiovascular events...
The cath lab staff UH Portage Medical Center.

The cath lab staff UH Portage Medical Center.

Feature | Cath Lab | September 09, 2019 | Anjan Gupta, M.D., FACC, FSCAI
Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute...
Overlay Init